Clinical Trials Directory

If you choose to join this study, you will:
- Have tumor tissue from a biopsy sent to a lab for genetic testing
-- If the tumor tissue has a genetic change that is targeted by one or more of the study drugs being tested in this study, you may be assigned to that study.

If you choose to join the study you will:

- Be in the study for 5 years  
- Have 8 study visits that will last 1-3 hours each and include physical exams, blood and urine tests, walk tests, imaging and questionnaires about how you're feeling

- Be randomized (like the flip of a coin) to receive either:
--- Transcatheter Mitral Valve Replacement (TMVR) with the Intrepid system
OR
--- Conventional mitral valve surgery
Both of these are inpatient procedures and require a 4-5 day hospital stay  

We are doing this study to see if the study drugs, domvanalimab and zimberelimab, are safe and effective for treating advanced or metastatic gastroesophageal adenocarcinoma.

We are doing this study to learn more about the effects of an experimental drug called RP1 (the study drug) for organ transplant recipients who have an advanced form of skin cancer.

We are doing this study to help young people with asthma better manage their medications in order to improve control of asthma symptoms. By improving control, we mean having fewer instances of wheezing, coughing, or chest tightness that require additional treatment by a doctor and increasing the time between asthma exacerbations.

We are doing this study to find out if an experimental drug called tabelecleucel is effective for the treatment of EBV-associated post-transplant lymphoproliferative disease (EBV+ PTLD). We want to know if it is beneficial for people with EBV+PTLD who have received either a solid organ transplant or an allogeneic hematopoietic cell transplant.

We are doing this study to find out if an investigational drug called T-DM1 (the study drug) is an effective treatment for HER2+ breast cancer when it is given as part of a regimen with trastuzumab injections. We will compare this regimen to the standard treatment of paclitaxel and trastuzumab.

We are doing this study to find out if an experimental drug called RGX-314 (the study drug) is a safe and effective treatment for wet macular degeneration (WMD). RGX-314 is an experimental gene therapy drug that is designed to make people's bodies produce a protein that blocks the production of a bodily substance called vascular endothelial growth factor (VEGF). We want to know if this drug can continually block the production of VEGF, which might help prevent fluid build-up in the eye.